Arizona Chemical Company, LLC

Solvay Pharmaceuticals, Gmbh

Kraton Chemical, LLC

Abbott Products Gmbh

Josephus Hubertus Maria Lange

Jochen Antel

Mark Schaapman

Peter-Colin Gregory

Michael Firnges

Erik Kelderman

Harald Waldeck

Dania B Reiche

Mark C Schaapman

Disclosed are compositions which include an ethylene polymer derived from at least one polar monomer with one or more ester groups, which polymerize with ethylene, (e.g., a copolymer derived from ethylene and vinyl acetate or a copolymer derived from ethylene and n-butyl acrylate) and a rosin ester. The rosin ester can have a low hydroxyl number (e.g., a hydroxyl number six or five or less), a low acid number (e.g., an acid number of ten or less), a low PAN number (e.g., a PAN number of eight or less), or combinations thereof. The compositions can exhibit improved viscosity stability and/or color stability and/or a decreased amount of char particle formation upon thermal aging.

Compositions containing ethylene polymers

Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one Kchannel opener as a first active agent and at least one CBcannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined Kchannel opening and CBantagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising Kchannel openers and CBantagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type 1, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhbition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined Kchannel opening and CBantagonistic properties.

Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions

Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a Kchannel modulator; and (ii) a CBmodulator. Also described herein are methods of making and using these compositions.

Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators

Growing community of inventors

Almere, Netherlands

Josephus Hubertus Maria Lange